Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00212212 · ClinicalTrials.gov registry record · NA
Selenium Supplementation of Patients With Cirrhosis
A NA study, sponsored by Vanderbilt University.
- Terminated
- Registry status
- NA
- Development phase
- 99
- Enrollment target
NCT00212212: Clinical Trial NA study, sponsored by Vanderbilt University.
NCT00212212 is a NA study that was terminated before completion, run by Vanderbilt University. The registered enrollment target is 99 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00212212, a NA study, was terminated before completion, sponsored by Vanderbilt University.
- TERMINATED
- Registry status
- NA
- Development phase
- 99 participants
- Enrollment target
Study Summary
This study is being conducted to determine if patients with cirrhosis (liver disease) are selenium deficient. The effect of supplementation with two chemical forms of selenium on plasma selenium biomarkers will be determined and correlated with the severity of the liver disease.
Interventions
- DIETARY_SUPPLEMENT placebo
- DIETARY_SUPPLEMENT selenium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2006-03 |
| Est. Completion | 2012-03 |
| Phase | NA |
Why NCT00212212 stopped before completion
NCT00212212 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00212212 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00212212 about?
NCT00212212 is a clinical study titled "Selenium Supplementation of Patients With Cirrhosis". This study is being conducted to determine if patients with cirrhosis (liver disease) are selenium deficient. The effect of supplementation with two chemical forms of selenium on plasma selenium biomarkers will be determined and correlated with the severity of the liver disease.
What is the current status of trial NCT00212212?
This trial is currently terminated. It is a NA study. The enrollment target is 99 participants. The study started on 2006-03. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00212212?
The interventions under investigation include: placebo (DIETARY_SUPPLEMENT), selenium (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00212212?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00212212's enrollment target sits among peer trials
99 920th of 2000 higher than 1,079 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia